BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250603
DTEND;VALUE=DATE:20250606
DTSTAMP:20260515T075329
CREATED:20250228T121911Z
LAST-MODIFIED:20250228T121911Z
UID:40598-1748908800-1749167999@www.pharmajournalist.com
SUMMARY:2nd Structure-Based Drug Design Summit
DESCRIPTION:With tightening budgets and increasing pressure to de-risk R&D\, pharma and biotech are shifting their focus toward smarter\, more efficient drug design. Companies are investing more in enabling technologies—from computational modeling and AI-driven predictions to structural biology techniques like Cryo-EM\, NMR\, and X-ray crystallography—to improve rational drug design and enhance decision-making early in discovery. \nWhile AI-powered structure prediction is transforming the landscape—recognized by the 2024 Nobel Prize for Google DeepMind’s AlphaFold2— its true impact depends on experimental validation. The ability to integrate computational insights with high-resolution structural data is now essential for unlocking complex targets and accelerating drug discovery. \nCryo-EM continues to push the limits of resolution for complex targets and Cryo-ET is emerging as a potential game-changer for biopharma – the future of structure-based drug design is here. \nThe 2nd Structure-Based Drug Design Summit is the only industry-dedicated meeting bringing together the latest advancements in integrative structural biology and computational tools to accelerate early drug discovery. Across three days of expert-led discussions and case studies\, you’ll gain insights into how leading scientists are leveraging Cryo-EM\, NMR\, X-ray crystallography\, and AI to solve high-value targets and drive rational drug design across small molecules\, peptides\, biologics\, and vaccines. \nWith coverage of design of TPDs\, molecular glues\, vaccines\, antibodies\, and mRNA\, GPCRs and membrane protein targeting therapeutics plus much more! \nThe field is evolving—don’t get left behind. Expand your network and join 80+ structural biologists\, medicinal chemists\, protein engineers\, and computational chemists in Boston this June and be part of the next wave of structure-based drug design innovation.
URL:http://www.pharmajournalist.com/event/2nd-structure-based-drug-design-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250609
DTEND;VALUE=DATE:20250612
DTSTAMP:20260515T075329
CREATED:20250304T113738Z
LAST-MODIFIED:20250304T113738Z
UID:40624-1749427200-1749686399@www.pharmajournalist.com
SUMMARY:Innovation in Psychosis Therapeutics Summit
DESCRIPTION:The Innovation in Psychosis Therapeutics Summit is the premier industry forum dedicated to advancing next-generation approaches for psychosis treatment. As 2025 marks a pivotal year for psychosis drug development—with a surge in clinical advancements and key collaborations gaining momentum—this inaugural event unites the brightest minds in biotech and pharma to overcome critical challenges in drug discovery and development. \n \nDesigned specifically for R&D leaders\, this summit is uniquely positioned to tackle the biggest hurdles in the field\, including translational validity\, patient heterogeneity\, placebo effect\, and trial scalability. By bringing together 60+ key stakeholders from discovery\, preclinical\, translational\, and clinical development\, this meeting provides a platform to collaborate\, exchange insights\, and shape the future of psychosis treatment. \nWith the growing urgency to address the significant unmet need in psychosis and the limitations of current atypical antipsychotics\, the time is now to drive innovation forward. Join the conversation as industry pioneers build on Cobenfy’s breakthrough success and explore cutting-edge strategies to develop more effective\, better-tolerated therapeutics across the psychosis spectrum. \nDon’t miss this brand-new opportunity to connect with thought leaders\, gain critical insights\, and be at the forefront of transforming psychosis R&D. \nTo know more visit: https://ter.li/9yj2vx
URL:http://www.pharmajournalist.com/event/innovation-in-psychosis-therapeutics-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250610
DTEND;VALUE=DATE:20250613
DTSTAMP:20260515T075329
CREATED:20250108T111946Z
LAST-MODIFIED:20250108T112021Z
UID:40293-1749513600-1749772799@www.pharmajournalist.com
SUMMARY:7th Annual Allogeneic Cell Therapies Summit
DESCRIPTION:With the autoimmune wave breathing financial life back into the allogeneic space\, and a growing number of oncology pipelines entering the clinic\, the allogeneic community are eagerly anticipating what lies ahead! \nMaking now the ideal time to attend the 7th Annual Allogeneic Cell Therapies Summit (June 10-12 | Boston\, MA)\, your flagship forum uniting the top allogeneic developers including Atara Bio\, Adicet Bio\, Senti Bio\, Glycostem and more. \nWhat Will 2025 Offer? \n\nGround-breaking Clinical Readouts: Dive into the latest results from CAR-T therapies with Atara Bio and Adicet Bio.\nSolid Tumor Breakthroughs: Hear from Senti Bio\, NKILT Therapeutics\, and Synaptimmune on how allogeneic therapies are targeting the tumor microenvironment to unlock entirely new indications.\nManufacturing at Scale: Learn how Tevogen and Cell BioEngines are navigating the complexities of scalable\, high-quality manufacturing to make these therapies commercially viable.\nBeyond Oncology: Broaden your scope by discovering how Biosyngen and Adicet Bio are leveraging allogeneic platforms to address autoimmune disorders.\n\nAs regulatory frameworks evolve to accommodate these revolutionary therapies and investment creeps back into allogeneic development\, staying informed is no longer optional. Get involved today to be part of the conversations solving today’s challenges and shaping tomorrow’s breakthroughs. \nFind out more: https://ter.li/o21go2
URL:http://www.pharmajournalist.com/event/7th-annual-allogeneic-cell-therapies-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250610
DTEND;VALUE=DATE:20250613
DTSTAMP:20260515T075329
CREATED:20250206T124225Z
LAST-MODIFIED:20250220T125930Z
UID:40428-1749513600-1749772799@www.pharmajournalist.com
SUMMARY:2nd Annual IMPACCT Real World Evidence Summit Europe
DESCRIPTION:This year’s IMPACCT Real World Evidence Europe conference is the only case-study led industry forum providing actionable insights into numerous challenges such as optimizing evidence generation plans in early stages\, enhancing collaboration between industry and public research to advance RWE\, consolidating cross-functional collaboration to improve effectiveness of RWE studies\, and exploring actionable study designs that empower patients to elevate RWE utility… \nAs regulators and payers increasingly elevate the importance of RWE in submission requirements and with an explosion of datasets opening up in parallel with advancing AI\, deep learning\, and large language models transforming big data analysis\, it has never been more critical to keep up with the matrix of country-specific regulatory nuances and industry case studies in optimizing integrated evidence plans\, bullet-proofing data quality\, and navigating vendor selection. \nThe 2nd IMPACCT Real World Evidence Summit Europe is the only industry meeting dedicated to uniting experts in RWE and Evidence Generation to consolidate\, innovate and apply RWE across the drug development lifecycle\, from external control arms to reimbursement. \nWith a tight focus on leveraging AI for both efficiency gains and big data analysis\, the latest on DARWIN and using RWE to support regulatory decision-making\, and creating a robust integrated evidence strategy\, join 60+ industry pioneers from AstraZeneca\, Pfizer\, Novartis\, Sanofi and more to collaboratively establish best practice and bridge the evidence gap between clinical research and practice\, ensuring resilience and success in a dynamic landscape as a successful business partner. \nJoin us\, our speakers\, attendees and sponsors to explore strategies\, learn efficient data deployment and automation\, learn best practices for sharing real-time data and insights cross-functionally\, inform your development processes\, address biases and study product life cycle management to bridge the gap from clinical trials to real-world evidence. \nWith over 50 industry pioneers we have the force to form a comprehensive evidence plan\, break free from silos\, and bridge the gap between clinical research and practice. Get in the room with Presidents\, VPs\, Directors\, Head\, Managers and Lead Scientists all on the same mission as you. \nThis is your one opportunity to liaise with like-minded\, driven and curious individuals about industry innovation. \nTo know more visit: https://ter.li/e8cs7v
URL:http://www.pharmajournalist.com/event/2nd-annual-impacct-real-world-evidence-summit-europe/
LOCATION:Steigenberger Airport Hotel\, Amsterdam\, Stationsplein Zuid-West 951\, Schiphol\, 1117 CE\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250610
DTEND;VALUE=DATE:20250613
DTSTAMP:20260515T075329
CREATED:20250409T111953Z
LAST-MODIFIED:20250409T111953Z
UID:40897-1749513600-1749772799@www.pharmajournalist.com
SUMMARY:Vendor Management & Outsourcing for Clinical Trials Summit
DESCRIPTION:Vendor management processes are crucial for ensuring compliance\, quality\, and timely delivery at every stage\, serving as the backbone of successful clinical trials. Acknowledging the transformative impact\, the industry is prioritizing the optimization of these intricate processes\, making significant investments to enhance key functions\, improve performance\, and maintain a competitive edge. Despite this professionals managing ancillary lab vendors and CROs lack a dedicated forum to address their unique challenges\, until now… \nIntroducing the Vendor Management & Outsourcing for Clinical Trials Summit\, built with the industry to the needs of vendor management\, outsourcing and clinical operations professionals. \nTo know more visit: https://ter.li/d1jemt
URL:http://www.pharmajournalist.com/event/vendor-management-outsourcing-for-clinical-trials-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250610
DTEND;VALUE=DATE:20250613
DTSTAMP:20260515T075329
CREATED:20250305T141309Z
LAST-MODIFIED:20250305T142300Z
UID:40667-1749513600-1749772799@www.pharmajournalist.com
SUMMARY:4th World ADC Asia Summit
DESCRIPTION:Linking the East to the West in the ADC World | 在ADC世界连接东西方 | ADC 세계에서 동서 연결하기ADCの世界で東西をつなぐ \nIn 2025\, Asia will continue leading ADC innovation\, with growth in dual-payload ADCs\, bispecific ADCs\, and novel linker-payload technologies. Staying informed through clinical updates\, connecting with new companies\, and building collaborations will be key to seizing emerging opportunities. \nThe 4th World ADC Asia Summit (June 10-12\, 2025\, | Incheon\, South Korea)\, part of the globally recognized World ADC series\, serves as the premier platform for showcasing the latest advancements in R&D\, clinical validation\, and commercialization. \nThis industry-leading event unites Asia’s top innovators with global expertise to drive ADC success across the region. \nWhat’s New in 2025? \n Three dynamic tracks covering discovery\, preclinical\, clinical\, and CMC\nExclusive seminar days on ADC fundamentals & Bispecific ADCs – Whether you’re just starting out or a seasoned expert\, the program offers something for professionals at every level\n Unparalleled networking with leading experts and organizations \nA Global Speaker Lineup \nWith 20+ new companies joining our esteemed panel from China\, Japan\, Korea\, Taiwan\, Singapore\, the US\, and Europe—featuring industry leaders such as AstraZeneca\, AbbVie\, HoneyBear Biosciences\, Chiome Bioscience\, and more—this is a must-attend event for anyone in the ADC field. \nLearn more here: https://ter.li/iimxna
URL:http://www.pharmajournalist.com/event/4th-world-adc-asia-summit/
LOCATION:Grand Hyatt Incheon\, 208 Yeongjonghaeannam-ro 321beon-gil\, Jung-gu\, Incheon\, South Korea
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250623
DTEND;VALUE=DATE:20250626
DTSTAMP:20260515T075329
CREATED:20250327T135543Z
LAST-MODIFIED:20250328T115442Z
UID:40760-1750636800-1750895999@www.pharmajournalist.com
SUMMARY:10th Annual Microbiome Movement Summit
DESCRIPTION:Returning for its 10th anniversary\, the Microbiome Movement Summit remains the premier global gathering for microbiome drug developers\, uniting experts across discovery\, preclinical\, translational\, regulatory\, and commercial sectors to drive innovation in the microbiome space. \nConnect with over 140+ experts from diverse fields within microbiome R&D\, including representatives from Pulmobiotics\, Seres Therapeutics\, BiomeBank\, and PharmaBiome. Engage in dynamic discussions\, forge valuable partnerships\, and gain actionable insights that will drive your microbiome research and development forward. This summit is your chance to be at the forefront of microbiome innovation and to collaborate with the brightest minds in the industry. \nWhat’s New for 2025? \n– Hear Brand New Insights from Industry Trailblazers: Gain key updates from leaders at Ferring Pharmaceuticals\, Siolta Therapeutics\, MaaT Pharma\, and Corundum Systems Biology as they discuss clinical advancements and commercial strategies shaping the future of microbiome therapeutics. \n– 18 New Organizations Taking the Stage: Discover the latest contributions from emerging companies such as Azitra\, Kanvas Bio\, Alveolus Bio\, Microviable Therapeutics\, Unilever\, Mikrobiomik\, Jona\, Nestle Health Science\, and more\, with each presenting their innovative approaches and breakthroughs in microbiome research. \n– Unlock the Next Wave of Microbiome-Based Drug Development: Explore groundbreaking synthetic biology innovations\, AI-driven strain engineering\, and advanced bioinformatics tools that are accelerating the discovery and optimization of microbiome-based therapies. \n– Advance Clinical Translation & Regulatory Success: Learn how companies are overcoming challenges in CMC\, large-scale manufacturing\, and regulatory approval\, with insights on recent FDA approvals\, IND-enabling studies\, and global market access strategies. \nGet your copy of the latest brochure here: https://ter.li/cdfr4c
URL:http://www.pharmajournalist.com/event/10th-annual-microbiome-movement-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250624
DTEND;VALUE=DATE:20250627
DTSTAMP:20260515T075329
CREATED:20250225T182337Z
LAST-MODIFIED:20250228T133908Z
UID:40588-1750723200-1750982399@www.pharmajournalist.com
SUMMARY:CPHI & PMEC China 2025
DESCRIPTION:CPHI & PMEC China is Asia’s premier pharmaceutical event for sourcing\, networking\, learning and innovation with over 20 years’ experience of bringing together Chinese and global pharma professionals. \n \nCPHI & PMEC China 2025 will cover more than 230\,000 square meters of exhibition area\, attract over 90\,000 global attendees and 3\,500 exhibitors\, and hold more than 100 conferences during the exhibition. \nCPHI & PMEC China 2025 showcases a wide range of pharmaceutical products and services\, including: active pharmaceutical ingredients\, Intermediates & fine chemicals\, excipients\, finished dosage formulation\, biopharmaceuticals\, natural extracts\, CMO & CRO\, machinery & equipment\, packaging & drug delivery\, laboratory equipment\, cleanroom & pollution control etc. \nClick here to register now.
URL:http://www.pharmajournalist.com/event/cphi-pmec-china-2025/
LOCATION:Shanghai New International Expo Centre\, Shanghai\, China
ORGANIZER;CN="Shanghai Sinoexpo Informa Markets International Exhibition Co.%2C Ltd.":MAILTO:CPHImarketing@imsinioexpo.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250624
DTEND;VALUE=DATE:20250627
DTSTAMP:20260515T075329
CREATED:20250304T114230Z
LAST-MODIFIED:20250304T114358Z
UID:40629-1750723200-1750982399@www.pharmajournalist.com
SUMMARY:5th Medical Device Software Development Summit
DESCRIPTION:The 5th Medical Device Software Development Summit is your must-attend opportunity to gain actionable strategies\, real-world case studies\, and expert insights to confidently develop\, secure\, and regulate cutting-edge medical device software – without compromise. \nDedicated to navigating the complexities of US and global regulations\, addressing cybersecurity vulnerabilities\, and managing legacy device updates\, this summit unites 120+ industry leaders – from medical device giants to innovative start-ups – to explore actionable strategies\, share best practices\, and collaborate on solutions for ensuring the continuous compliance and security of cutting-edge software in a rapidly evolving market. \nWhat Will you Gain: \n\nStay Ahead of Regulatory Changes: Gain insights from Biogen\, Werfen\, and Olympus on the latest FDA\, EU MDR\, and global compliance updates\, ensuring your products meet evolving standards.\nSecure & Accelerate Your Software: Learn how Medtronic\, RETINA-AI\, and Abbott are addressing cybersecurity risks\, enhancing software validation\, and leveraging AI-powered innovation to streamline development processes.\nUnlock AI for Safer\, Faster Development: Discover how HeartSciences\, Kheiron\, and Globe Biomedical are utilizing AI to expedite software testing\, improve validation\, and bolster cybersecurity\, leading to safer and more efficient medical device development.\n\n\nDon’t miss this summit – join us in Boston this June to stay ahead\, gain crucial insights\, benchmark and fuse knowledge from software\, QA\, RA and product teams to align innovation in software with evolving processes\, cybersecurity\, and global regulatory frameworks in new and legacy devices. \nView the full Event Guide here: https://ter.li/cziksw
URL:http://www.pharmajournalist.com/event/5th-medical-device-software-development-summit/
LOCATION:The Royal Sonesta Boston\, 40 Edwin H Land Blvd\, Cambridge\, MA\, 02142\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250624
DTEND;VALUE=DATE:20250627
DTSTAMP:20260515T075329
CREATED:20250409T112357Z
LAST-MODIFIED:20250409T112504Z
UID:40904-1750723200-1750982399@www.pharmajournalist.com
SUMMARY:8th International Neoantigen Summit
DESCRIPTION:2024 saw a wealth of clinical progression with Nouscom\, CureVac\, Transgene and other pioneering companies paving the way for neoantigen based vaccines and therapies to become tolerable\, durable medicines to effectively treat cancer.\nReady to unite the global neoantigen community\, the 8th International Neoantigen Summit 2025 returns to address key challenges in the discovery\, translation and clinical development of safe and cost-effective neoantigen therapies and vaccines to attract investors and ultimately improve the health of patients. \nJoin neoantigen leaders from the likes of AstraZeneca\, Geneos Therapeutics\, Evaxion Biotech and many more at this end-to-end meeting\, focusing on the development of durable\, neoantigen cancer vaccines and cell therapies. With the potential to deliver safe\, efficacious personalized or off-the-shelf therapeutic options to patients\, this is your chance to collaborate and accelerate the translation of neoantigen-based therapies from discovery to clinical success. \nTo know more visit: https://ter.li/zdfjes
URL:http://www.pharmajournalist.com/event/8th-international-neoantigen-summit/
LOCATION:Steigenberger Airport Hotel Amsterdam\, Stationsplein Zuid-West 951\, 1117 CE Schiphol\, Netherlands\, 1117 CE\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250625
DTEND;VALUE=DATE:20250627
DTSTAMP:20260515T075329
CREATED:20250401T093821Z
LAST-MODIFIED:20250401T093821Z
UID:40798-1750809600-1750982399@www.pharmajournalist.com
SUMMARY:5th Annual Induced Proximity-Based Drug Discovery Summit
DESCRIPTION:Coming to San Diego\, CA for the first time\, the 5th Induced Proximity-Based Drug Discovery Summit returns as your intimate learning and networking setting to cover the depth and breadth of proximity-based drugs from stabilization\, phosphorylation and methylation to novel lysosome-based degradation to finally drug the undruggable. \nEnabling leaders in biopharma and academia to identify novel MoAs\, leverage advanced technologies to find targets more efficiently\, and optimize chemical structures for more effective therapeutic agents for a wide range of disease areas. Alongside key strategic updates on DUBTACs\, RIPTACs\, tPRIMEs\, RiboTACs and more\, it provides granular technical and scientific insights to overcome challenges in accessing diverse chemical matter and designing selective\, potent small molecules of tomorrow. \nJoin 70+ experts in drug discovery\, medicinal chemistry\, chemical biology and structural biology from leading companies such as Genentech\, Halda Therapeutics and Stablix and gain access to genuinely innovative research from breakthrough companies and academic labs pioneering the next generation of induced proximity-based drugs beyond the ubiquitin proteasome system \nDownload the event guide for full details: https://ter.li/blor1c
URL:http://www.pharmajournalist.com/event/5th-annual-induced-proximity-based-drug-discovery-summit/
LOCATION:The Westin San Diego Bayview\, 400 W Broadway\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250626
DTEND;VALUE=DATE:20250628
DTSTAMP:20260515T075329
CREATED:20250404T112624Z
LAST-MODIFIED:20250404T112624Z
UID:40863-1750896000-1751068799@www.pharmajournalist.com
SUMMARY:4th Liquid Biopsy for Precision Oncology East Coast
DESCRIPTION:The 4th Liquid Biopsy for Precision Oncology East Coast Summit returns to Boston with a refreshed agenda\, sharpened focus\, and a renewed mission: to accelerate access to more sensitive\, less invasive testing by addressing the most pressing challenges across the entire patient care continuum. \nThis year\, we’ve updated the Summit’s name and expanded its scope. What began with a focus on early detection and recurrence monitoring has grown to reflect the full breadth of innovation across the liquid biopsy space – from MRD and treatment response to emerging applications in rare diseases\, novel analytes\, and beyond. \nBringing together leaders in Biomarker Development\, Translational Research\, Diagnostics\, Clinical Development\, Pathology\, and beyond\, this is the go-to East Coast forum for diving deep into the barriers slowing the adoption of liquid biopsy technologies. \nTake home actionable insights to ensure you’re maximizing the value of liquid biopsies in your therapeutic development strategies. Shape the future of precision oncology and be part of the conversations that will drive meaningful change for patients worldwide. \nWhat’s more\, this event is completely *FREE for drug developers and researchers for the entire 2 day conference\, so claim your pass here (it only takes 2 minutes): https://ter.li/mr0yvh \nIf you need to explore the full event guide in more detail\, feel free to download the brochure here: https://ter.li/mxugsc \nT&Cs are available on the website.
URL:http://www.pharmajournalist.com/event/4th-liquid-biopsy-for-precision-oncology-east-coast/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR